ESMO GI 2024 Insights: 1L Unresectable HCC - Outcomes by Comorbidities With STRIDE (Durvalumab & Tremelimumab Regimen) in the HIMALAYA Study

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

ESMO GI 2024 Insights: 1L Unresectable HCC - Outcomes by Comorbidities With STRIDE (Durvalumab & Tremelimumab Regimen) in the HIMALAYA Study

By Insights from 2024 ESMO GI Annual Meeting FEATURING Lorenza Rimassa

0 views

July 5, 2024

Comments 0

Explore the mechanism of Action of a TKI in HCC

Feat. W. Keiser

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl